Skip to main content
  • Saved

made a Post

Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report - PubMed

Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report - PubMed

Source :

https://pubmed.ncbi.nlm.nih.gov/33842645/

Immunotherapy has been proved to be a promising candidate for advanced non-small cell lung cancer (NSCLC). Despite MET mutations are regarded as an independent factor of programmed death ligand 1 (PD-L1) high expression, the efficacy of immune checkpoint inhibitors (ICIs) across NSCLC harboring Mese ...